Skip to main content

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-05-2009 | editorial

In search of a better platelet ADP-receptor blocker

Auteur: F. W. A. Verheugt

Gepubliceerd in: Netherlands Heart Journal | Uitgave 5/2009

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

The second-generation antiplatelet agents – the inhibitors of the ADP receptor – have proven important in the management of acute coronary syndromes with or without coronary intervention.
Literatuur
1.
go back to reference CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502. CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
2.
go back to reference Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.
3.
go back to reference Sabatine M, Cannon CP, Montalescot G, et al. Fibrinolysis with double antiplatelet therapy in ST-elevation acute coronary syndromes. N Engl J Med 2005:352:1179–89. Sabatine M, Cannon CP, Montalescot G, et al. Fibrinolysis with double antiplatelet therapy in ST-elevation acute coronary syndromes. N Engl J Med 2005:352:1179–89.
4.
go back to reference Chen ZM, Jiang LX, Chen Y, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607–21. Chen ZM, Jiang LX, Chen Y, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607–21.
5.
go back to reference Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597–603. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597–603.
6.
go back to reference Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-Thrombolysis in Myocardial Infarction-44 Trial. Circulation 2007;116:2923–32. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-Thrombolysis in Myocardial Infarction-44 Trial. Circulation 2007;116:2923–32.
7.
go back to reference Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.
8.
go back to reference Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine phosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-elevation acute coronary syndromes: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50:1844–51. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine phosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-elevation acute coronary syndromes: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50:1844–51.
9.
go back to reference Bouman HJ, van Werkum JW, Hackeng CM, Clappers N, ten Berg JM. Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel pretreated subjects. Neth Heart J 2009;17:195–8. Bouman HJ, van Werkum JW, Hackeng CM, Clappers N, ten Berg JM. Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel pretreated subjects. Neth Heart J 2009;17:195–8.
Metagegevens
Titel
In search of a better platelet ADP-receptor blocker
Auteur
F. W. A. Verheugt
Publicatiedatum
01-05-2009
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 5/2009
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086244